Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment

Approximately 30% of pancreatic cancer patients harbor targetable mutations. However, there has been no therapy targeting these molecules clinically. Nucleic acid medicines show high specificity and can target RNAs. Nucleic acid medicine is expected to be the next-generation treatment next to small...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakawa, Keiko, Nakano-Narusawa, Yuko, Hashimoto, Nozomi, Yokohira, Masanao, Matsuda, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747711/
https://www.ncbi.nlm.nih.gov/pubmed/31470511
http://dx.doi.org/10.3390/ijms20174224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747711/
https://www.ncbi.nlm.nih.gov/pubmed/31470511
http://dx.doi.org/10.3390/ijms20174224

Ejemplares similares